Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 4 2Phase 3 2Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vomiting 2Uterine Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Aprepitant 8Palonosetron 6Dexamethasone 6Granisetron 3fosaprepitant 2dexamethasone 21-phosphate 2Tropisetron 2Ondansetron 2Metoclopramide 2Calcium Dobesilate 2ramosetron 1naldemedine 1gamma-Aminobutyric Acid 1dolasetron 1dexamethasone acetate 1alizapride 1Tablets 1Spinal Puncture 1Saline Solution 1Population Groups 1Olanzapine 1Myelography 1Duration of Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Vomiting × fosaprepitant × Clear all
NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Not yet recruiting
1,028 enrolled
Breast

Breast Neoplasms, Vomiting

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡